en-TAK-a-pone 
Contraindicated in:
Use Cautiously in:
CV: hypotension.
Derm: MELANOMA.
GI: abdominal pain, colitis, diarrhea, nausea (during initiation), retroperitoneal fibrosis.
GU: brownish-orange discoloration of urine.
MS: dyskinesia, RHABDOMYOLYSIS.
Neuro: aggressive behavior, agitation, confusion, delirium, disorientation, dizziness, hallucinations, NEUROLEPTIC MALIGNANT SYNDROME, paranoid ideation, syncope, urges (gambling, sexual).
Resp: pleural effusion, pleural thickening, pulmonary infiltrates.
Drug-Drug:
(Generic available)
Absorption: 35% absorbed following oral administration; absorption is rapid.
Distribution: Widely distributed to tissues.
Protein Binding: 98%.
Metabolism/Excretion: Minimal amounts excreted unchanged; highly metabolized followed by biliary excretion.
Half-life: Initial phase: 0.4–0.7 hr; second phase: 2.4 hr.
NDC Code*